# Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

> **NCT05876806** · PHASE2 · UNKNOWN · sponsor: **Se Jun Park** · enrollment: 30 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05876806
- **Lead sponsor:** Se Jun Park
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-20
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876806, "Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05876806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*